MGUS rarely earns a compensable VA rating on its own, because VA rates it at zero percent unless it turns symptomatic or moves into multiple myeloma. In the guides we publish here, what we see veterans get wrong most often about MGUS is assuming it still needs its own proof of service connection. A lot of older claims guides never caught up with the PACT Act update that changed that.
Monoclonal gammopathy of undetermined significance, or MGUS, is a condition where abnormal plasma cells in the bone marrow produce a single atypical protein, called an M-protein, that shows up on routine bloodwork. Most veterans with MGUS have no symptoms at all. Doctors monitor it with regular labs instead of treating it, because only a small share of cases go on to develop into multiple myeloma or a related blood cancer such as amyloidosis or Waldenstrom macroglobulinemia.
MGUS itself is a presumptive condition, not just multiple myeloma. The Department of Veterans Affairs (VA) added MGUS to its Agent Orange presumptive conditions list under the PACT Act. Multiple myeloma, the cancer MGUS can progress into, was already on that list.
What Is MGUS?
MGUS is a plasma cell disorder, not a cancer, though doctors watch it closely because of what it can become. Plasma cells are a type of white blood cell that normally makes antibodies to fight infection. In MGUS, a small group of abnormal plasma cells makes one identical, non-functional protein instead, the M-protein, which a standard blood test can detect long before any symptom shows up.
For most veterans, MGUS stays exactly where it is. The risk of progression to multiple myeloma or a related blood cancer is low, which is why VA and civilian doctors alike manage it with periodic bloodwork rather than active treatment. That low but real progression risk is also why a diagnosis still belongs in your VA file, even when it carries no rating yet.
Is MGUS on VA's Agent Orange Presumptive List?
Yes. VA added monoclonal gammopathy of undetermined significance to its Agent Orange presumptive conditions list under the PACT Act, a 2022 law that expanded presumptive coverage for veterans exposed to herbicides and other toxic substances during military service. MGUS is listed alongside multiple myeloma on VA's own Agent Orange presumptive conditions page. A presumptive listing means VA assumes your MGUS is connected to qualifying herbicide exposure, so you do not have to prove the two are linked through medical evidence.
Qualifying exposure generally covers:
- Service in Vietnam or its inland waterways during the Vietnam War era
- Service aboard a ship in the waters off the coast of Vietnam, covered by the Blue Water Navy Vietnam Veterans Act
- Service in, near, or around C-123 aircraft that previously sprayed Agent Orange
- Service in other locations the PACT Act added, including Thailand, Laos, Cambodia, Guam, American Samoa, and Johnston Atoll
For the complete presumptive conditions list and how VA verifies each exposure category, see our VA Agent Orange Presumptive Conditions: Claims Guide. Our Agent Orange History: Vietnam to the PACT Act Timeline guide traces how MGUS and other conditions got added over time, and our Agent Orange 2026 Additions: New Presumptive Conditions & Locations guide covers the newest changes to the list.
Veterans without one of those service records still need to connect MGUS to their time in uniform directly, or through a condition VA has already service-connected. The direct and secondary paths below cover how that works.
MGUS VA Disability Rating Under Diagnostic Code 7712
VA does not have a rating code written just for MGUS as a stand-alone diagnosis. Instead, 38 CFR 4.117 folds MGUS into Diagnostic Code 7712 alongside multiple myeloma. Asymptomatic or smoldering MGUS gets a zero percent rating under that code, the same non-compensable rating asymptomatic or smoldering multiple myeloma receives. Symptomatic multiple myeloma gets a 100 percent rating instead.
A zero percent rating still matters. A service-connected diagnosis, even at zero percent, puts a claim on file, opens VA health care tied to that condition, and gives a foundation for any secondary condition MGUS causes later. It also keeps VA aware of the diagnosis if the M-protein level climbs or symptoms start.
Some veterans develop symptoms MGUS itself does not fully explain, such as fatigue tied to early anemia or nerve pain from the abnormal protein. VA can rate those residuals under whichever diagnostic code covers that body system, using the rating-by-analogy rule in 38 CFR 4.20. That rule lets a rater apply the closest matching diagnostic code when a condition has no listed code of its own, as long as the affected body system and symptoms genuinely line up. The regulation bars conjectural analogies, so a rater needs real clinical findings connecting the symptom to MGUS before borrowing a code from elsewhere.
If MGUS Progresses to Multiple Myeloma
Bloodwork or a bone marrow biopsy showing MGUS has moved into active multiple myeloma changes the rating right away. Symptomatic multiple myeloma rates at 100 percent under Diagnostic Code 7712, and that evaluation continues for five years after diagnosis regardless of how treatment goes. VA schedules a mandatory exam at the five-year mark to reassess the rating, and any reduction after that exam follows the same procedural protections that apply to other VA disability rating reductions.
For a veteran whose Agent Orange exposure already qualifies, both the MGUS diagnosis and the multiple myeloma diagnosis connect to service without a nexus opinion. That sequencing can matter for back pay. When MGUS shows up in your medical records well before multiple myeloma develops, those earlier records can support an earlier effective date for the underlying claim, since the presumptive connection to herbicide exposure existed from the MGUS diagnosis onward. An accredited veterans service officer or attorney can review whether your specific medical timeline supports that argument, because effective-date rules turn on the exact evidence in your file.
Direct and Secondary Service Connection for MGUS
Not every veteran with MGUS has Agent Orange exposure on their record. Direct service connection is still available without it, built the way most VA disability claims are: a current diagnosis, plus evidence connecting its onset to something that happened in service. For MGUS specifically, that evidence is often a documented chemical or industrial exposure outside the Agent Orange categories, or another exposure such as burn pits or contaminated water. It can also be another in-service event a doctor can plausibly tie to abnormal plasma cell activity years later.
Secondary service connection is a separate path. It applies when MGUS developed because of a condition VA has already connected to your service, or because of the treatment for that condition. Long-term use of certain medications, chronic inflammation from an existing service-connected illness, or radiation treatment for an earlier service-connected cancer are the kinds of chains that can support a secondary claim. A nexus letter from a treating physician or an independent medical examiner usually has to spell out that connection in medical terms, since VA raters are not doctors and will not infer it on their own. Our What Is a Nexus Letter? VA Claims Guide 2026 covers what a strong one needs to include.
Evidence That Supports an MGUS Claim
Whether you are filing on a presumptive basis or building a direct or secondary claim, the same core evidence carries the file:
- Bloodwork showing the M-protein level and any change in it over time
- Oncology or hematology records documenting the MGUS diagnosis and any monitoring plan
- Service and exposure records, such as your DD-214 and deployment orders, that place you in a qualifying location
- A nexus opinion from a treating doctor or independent medical examiner, for claims that fall outside the presumptive category
A VA Compensation and Pension (C&P) exam typically follows once you file. A VA-contracted examiner reviews your records and current bloodwork at that exam to confirm the diagnosis and its severity.
Secondary Conditions Linked to MGUS
MGUS and multiple myeloma can trigger problems in other body systems, and those problems can carry their own rating even when the underlying blood condition sits at zero percent. Veterans with MGUS sometimes develop peripheral neuropathy from the abnormal protein affecting nerve function, kidney damage from protein deposits filtering through the kidneys, anemia from reduced healthy blood cell production, or bone lesions and fractures once myeloma sets in. Each of those has its own diagnostic code, and each can be claimed on its own once a doctor connects it to the MGUS or myeloma diagnosis already on file. Filing those secondary claims separately, rather than assuming the original MGUS rating covers them, often makes the difference. It can mean a zero percent evaluation becomes a combined rating that reflects what the condition is doing to your health.
When MGUS or Myeloma Treatment Stops You from Working
A 100 percent schedular rating for symptomatic multiple myeloma already reflects total disability, so most veterans in active treatment do not need a separate path to full compensation. The gap shows up for veterans whose combined ratings from MGUS-related secondary conditions add up to less than 100 percent on paper, but whose symptoms or treatment schedule still make full-time work impossible. That is the situation Total Disability based on Individual Unemployability, or TDIU, is built for. Our TDIU Explained: 100% VA Pay Without 100% Rating guide covers how VA evaluates that claim and what it takes to qualify.
If you are working through an MGUS VA disability rating claim, start by pulling your bloodwork history, oncology notes, and service records together before you file. Then loop in an accredited veterans service officer to check whether your exposure history supports the presumptive path.
This is general information, not legal or financial advice. Verify your specific situation with the VA or an accredited veterans service officer.